SERUM EXTRACELLULAR VESICLE-DERIVED CIRCHIPK3 AND CIRCSMARCA5 ARE TWO NOVEL DIAGNOSTIC BIOMARKERS FOR GLIOBLASTOMA MULTIFORME

Glioblastoma multiforme (GBM) is the most frequent and deadly human brain cancer. We propose the use of serum extracellular vesicle (sEV)-derived circular RNAs (circRNAs) as highly stable, minimally invasive biomarkers for GBM diagnosis. EVs were isolated by size exclusion chromatography from sera of 23 GBM and 5 grade 3 glioma (GIII) patients, and 10 unaffected controls (UC). The expression of two candidate circRNAs (circSMARCA5 and circHIPK3) was assayed by droplet digital PCR. CircSMARCA5 and circHIPK3 were significantly less abundant in sEVs from GBM patients with respect to UC (-2.15 and -1.92 fold, respectively) and GIII (−1.75 and −1.4 fold, respectively). Receiver operating characteristic curve (ROC) analysis, based on the expression of sEV-derived circSMARCA5 and circHIPK3, allowed to distinguish GBM from UC (AUCs = 0.823 (0.667–0.979) and 0.855 (0.704 to 1.000), with a 95% confidence interval (CI), respectively). Multivariable ROC analysis, performed by combining the expression of sEV-derived circSMARCA5 and circHIPK3 with preoperative neutrophil to lymphocyte (NLR), platelet to lymphocyte (PLR) and lymphocyte to monocyte (LMR) ratios (three known diagnostic and prognostic GBM markers) allowed an improvement in the GBM diagnostic accuracy (AUC 0.901 (0.7912 to 1.000), 95% CI). Our data suggest sEV-derived circSMARCA5 and circHIPK3 as good diagnostic biomarkers for GBM, especially when associated with preoperative NLR, PLR and LMR.